Altamira Therapeutics Ltd. Revenue Of Combined Entity
Altamira Therapeutics Ltd. (CYTOF) reported Revenue Of Combined Entity of CHF 305.62 thousand for the 12-month period ending 2022-12-31, per its 20-F filed 2023-05-16.
Discontinued › Income Statement › Other Income
ifrs-full:RevenueOfCombinedEntity · last filed 2023-05-16
| Period end | Revenue Of Combined Entity 12 month |
|---|---|
| 2022-12-31 | 305.62K CHF 20-F · filed 2023-05-16 |
| 2021-12-31 | 63.88K CHF 20-F · filed 2023-05-16 |